{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:34:04Z","timestamp":1789842844028,"version":"4.0.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,19]]},"DOI":"10.7759\/cureus.77652","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T11:47:22Z","timestamp":1737287242000},"source":"Crossref","is-referenced-by-count":2,"title":["Severe Hepatotoxicity From Capmatinib: A Case Report and Therapeutic Approach"],"prefix":"10.7759","author":[{"given":"Mina","family":"Aiad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh J","family":"Bhalala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halle","family":"Bagshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Starner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasmita","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier C","year":"2003","unstructured":"Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003, 4:915-25. 10.1038\/nrm1261","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref2","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2017). Accessed. 10\/01\/2024: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf."},{"key":"ref3","unstructured":"Label. TABRECTA- capmatinib tablet, film coated. (2024). Accessed: 10\/01\/2024: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100563","article-title":"Capmatinib-induced liver injury as emerging toxicity of MET inhibitors in patients with NSCLC pretreated with immune checkpoint inhibitors","volume":"4","author":"Sisi M","year":"2023","unstructured":"Sisi M, Vitale G, Fusaroli M, et al.. Capmatinib-induced liver injury as emerging toxicity of MET inhibitors in patients with NSCLC pretreated with immune checkpoint inhibitors. JTO Clin Res Rep. 2023, 4:100563. 10.1016\/j.jtocrr.2023.100563","journal-title":"JTO Clin Res Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0306068101","article-title":"Hepatocyte growth factor\/c-met signaling pathway is required for efficient liver regeneration and repair","volume":"101","author":"Huh CG","year":"2004","unstructured":"Huh CG, Factor VM, S\u00e1nchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor\/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A. 2004, 101:4477-82. 10.1073\/pnas.0306068101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2016.08.015","article-title":"The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice","volume":"261","author":"Shaker ME","year":"2016","unstructured":"Shaker ME, Ashamallah SA, El-Mesery M. The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice. Toxicol Lett. 2016, 261:13-25. 10.1016\/j.toxlet.2016.08.015","journal-title":"Toxicol Lett"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.090324","article-title":"Absorption, distribution, metabolism, and excretion of capmatinib (INC280) in healthy male volunteers and in vitro aldehyde oxidase phenotyping of the major metabolite","volume":"48","author":"Glaenzel U","year":"2020","unstructured":"Glaenzel U, Jin Y, Hansen R, et al.. Absorption, distribution, metabolism, and excretion of capmatinib (INC280) in healthy male volunteers and in vitro aldehyde oxidase phenotyping of the major metabolite. Drug Metab Dispos. 2020, 48:873-85. 10.1124\/dmd.119.090324","journal-title":"Drug Metab Dispos"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.08.023","article-title":"Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene","volume":"82","author":"Krausova L","year":"2011","unstructured":"Krausova L, Stejskalova L, Wang H, Vrzal R, Dvorak Z, Mani S, Pavek P. Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. Biochem Pharmacol. 2011, 82:1771-80. 10.1016\/j.bcp.2011.08.023","journal-title":"Biochem Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"1","author":"Wolf J","year":"2024","unstructured":"Wolf J, Hochmair M, Han JY, et al.. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 2024, 1:1357-70. 10.1016\/S1470-2045(24)00441-8","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9118","article-title":"Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-na\u00efve patients with advanced non-small cell lung cancer (NSCLC) with high tumor PD-L1 expression: results of a randomized, open-label, multicenter, phase 2 study","volume":"40","author":"Tony","year":"2022","unstructured":"Tony, Cortinovis DL, Majem M, et al.. Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-na\u00efve patients with advanced non-small cell lung cancer (NSCLC) with high tumor PD-L1 expression: results of a randomized, open-label, multicenter, phase 2 study. J Clin Oncol. 2022, 40:9118. 10.1200\/JCO.2022.40.16_suppl.9118","journal-title":"J Clin Oncol"},{"key":"ref11","unstructured":"Highlights of prescribing information. (2020). Accessed. 10\/01\/2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213591s000lbl.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/333906-severe-hepatotoxicity-from-capmatinib-a-case-report-and-therapeutic-approach","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T11:47:24Z","timestamp":1737287244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/333906-severe-hepatotoxicity-from-capmatinib-a-case-report-and-therapeutic-approach"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,19]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.77652","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,19]]}}}